Avalo acquires Phase 2-ready anti-IL-1ß mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026 Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T.
why cant they all do this
LL
Always consult an Investment Professional, my posts are my own opinions, and not for investing decisions
L
